Virginia Pubul, a,b,* Irene Casans, c Santiago Aguadé, d,e and Francisco Javier de Haro a,e

a Grupo de Trabajo de Cardiología Nuclear de la Sociedad Española de Medicina Nuclear e Imagen Molecular, Madrid, Spain
b Servicio de Medicina Nuclear, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain
c Servicio de Medicina Nuclear, Hospital Clínico Universitario, Valencia, Spain
d Servicio de Medicina Nuclear, Hospital Universitario Vall d’Hebron, Barcelona, Spain
e Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

* Corresponding author:
E-mail address: virginia.pubul.nunez@sergas.es (V. Pubul).
Available online 31 July 2017

REFERENCES


SEE RELATED CONTENT:
http://dx.doi.org/10.1016/j.rec.2016.12.041
http://dx.doi.org/10.1016/j.rec.2017.07.004
http://dx.doi.org/10.1016/j.rec.2017.01.004
http://dx.doi.org/10.1016/j.rec.2017.07.005
1885–5857/ © 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.


Puntualizaciones al documento de consenso en cardio-oncología y a la revisión sobre técnicas de imagen cardiaca en detección de cardiotoxicidad. Respuesta

To the Editor,

Heart failure is one of the most concerning and best studied complications of antitumor treatments. Existing literature suggest that surveillance strategies are needed to promote early diagnosis at stages when cardiac dysfunction may be reversible with appropriate therapy. 1–3 Regardless of the technique used for cancer treatment monitoring, it is clear that left ventricular ejection fraction alone is not sufficient to detect early myocardial injury. 4 Current guidelines recommend echocardiography as the method of choice for the longitudinal follow-up of cancer patients. 1–3

The main limitations of isotopic ventriculography are both the repeated use of radiation and the limited information on heart function. In fact, the high reproducibility of left ventricular ejection fraction measurements reported in the past is not available with current gamma cameras. 5–16 Echocardiography offers a complete evaluation of the heart (right ventricular function, atrial function, valvular and pericardial disease) 7 and new echo techniques, particularly myocardial deformation imaging, allow for an early diagnosis of subclinical changes in cardiac function. 8 Therefore, in daily practice, isotopic ventriculography is suggested only when echocardiography or cardiac-magnetic resonance imaging are not available and it has a low impact as an imaging technique for the diagnosis and prevention of cardiotoxicity. 1–3,6

Teresa López-Fernández, a,* Paaladinesh Thavendiranathan, b José Luis López-Sendón, a and Juan Carlos Plana Gómez c

a Servicio de Cardiología, Unidad de Imagen Cardíaca, Unidad de Cardio-Oncología, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
b Peter Munk Cardiac Center, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada
c Section of Cardiology, Baylor College of Medicine, Houston, Texas, United States

* Corresponding author:
E-mail address: tiferandez8@gmail.com (T. López-Fernández).
Available online 31 July 2017

REFERENCES


SEE RELATED CONTENT:
http://dx.doi.org/10.1016/j.rec.2017.07.005
http://dx.doi.org/10.1016/j.rec.2017.07.004

1885-5857/
© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.